相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
Xin Wang et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate
Rosario F. Di Stefano et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2021)
Serum testosterone levels and testosterone 'bounce' phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer
Yu Guang Tan et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)
Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
Yi-Ting Lin et al.
FRONTIERS IN PHARMACOLOGY (2021)
Second-line Hormonal Therapy for the Management of Metastatic Castration-resistant Prostate Cancer: a Real-World Data Study Using a Claims Database
Jui-Ming Liu et al.
SCIENTIFIC REPORTS (2020)
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
Simon Chowdhury et al.
TARGETED ONCOLOGY (2020)
Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies
Omar Abdel-Rahman
CLINICAL GENITOURINARY CANCER (2019)
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Meghan A. Rice et al.
FRONTIERS IN ONCOLOGY (2019)
Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
Yu Hirata et al.
PROSTATE INTERNATIONAL (2019)
Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer
Rachael McCool et al.
VALUE IN HEALTH (2018)
Comparison of Propensity Score Methods and Covariate Adjustment Evaluation in 4 Cardiovascular Studies
Markus C. Elze et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison
Akhil Chopra et al.
PROSTATE (2017)
Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials
Minyong Kang et al.
ONCOTARGET (2017)
Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison
Haofeng Zheng et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Comparison of Toxicity and Efficacy Outcomes of Abiraterone and Enzalutamide in 198 Patients with Metastatic Castrate Resistant Prostate Cancer
T. Norris et al.
CLINICAL ONCOLOGY (2017)
Uncontrolled diabetes predicts poor response to novel antiandrogens
Theodoros Karantanos et al.
ENDOCRINE-RELATED CANCER (2016)
Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer
Giorgio Gandaglia et al.
EUROPEAN UROLOGY (2015)
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
Peter C. Austin et al.
STATISTICS IN MEDICINE (2015)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson et al.
NATURE REVIEWS CANCER (2015)
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
D. Bianchini et al.
EUROPEAN JOURNAL OF CANCER (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
R. J. van Soest et al.
EUROPEAN JOURNAL OF CANCER (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer
Fred Saad
THERAPEUTIC ADVANCES IN UROLOGY (2013)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Characterising the castration-resistant prostate cancer population: a systematic review
M. Kirby et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
